Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
This dividend fund is down only 3% this year vs. the S&P's 20% decline. Here are the manager's top stock picks.
11:25am, Friday, 24'th Jun 2022 MarketWatch
John Kornitzer explains why the Buffalo Flexible Income Fund has held up so well during the bear market.
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug
05:18pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.
LabCorp (LH) Partners HealthVerity to Grow in Drug Development
01:47pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.
Stocks Rebound Strongly; Exxon Mobil, Dollar General, Eli Lilly In Focus | Stock Market Today
04:45pm, Tuesday, 21'st Jun 2022
Nice session, but market rally isn't confirmed yet. Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: investors.com Like us on Facebook: https://www.facebook.com/in
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
09:50pm, Monday, 20'th Jun 2022 Zacks Investment Research
In the latest trading session, Eli Lilly (LLY) closed at $290.90, marking a +0.98% move from the previous day.
LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test
04:06pm, Monday, 20'th Jun 2022 Zacks Investment Research
LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.
Why Eli Lilly's Immunology Prospects Look Promising
12:30pm, Monday, 20'th Jun 2022 The Motley Fool
Uplifting news turns the tide in immunology.
The Zacks Analyst Blog Highlights Lilly, Merck, Roche, Pfizer and Moderna
09:24am, Monday, 20'th Jun 2022 Zacks Investment Research
Lilly, Merck, Roche, Pfizer and Moderna have been included in this Analyst Blog.
Why Eli Lilly's Immunology Prospects Look Promising
08:30am, Monday, 20'th Jun 2022
Uplifting news turns the tide in immunology.
Pharma Stock Roundup: FDA Panel Nod for PFE, MRNA Young Kids' COVID Jabs & More
12:37pm, Friday, 17'th Jun 2022 Zacks Investment Research
FDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
12:31pm, Friday, 17'th Jun 2022 Zacks Investment Research
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
10:50am, Friday, 17'th Jun 2022
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Eli Lilly and Company (LLY) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)
04:16pm, Tuesday, 14'th Jun 2022
Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 43rd Annual Global Healthcare Conference June 14, 2022 1:40 PM ET Company Participants Anne White - SVP and President, Lilly Neuroscience Mark Mintun -
Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata
02:41pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.
Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata
12:24pm, Tuesday, 14'th Jun 2022
Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.
